Dr. Daniel J. DeAngelo


Chief, Division of Leukemia , Experience: 25

Book Appointment

About Doctor

Dr. DeAngelo received his MD and PhD from Albert Einstein College of Medicine in 1993, followed by residency in internal medicine at Massachusetts General Hospital. He served a clinical fellowship in hematology and oncology at the Brigham and Women’s Hospital and Dana-Farber Cancer Institute, where he joined the staff in 1999.

Board Certification:

  • Hematology, 2000
  • Internal Medicine
  • Medical Oncology, 1999

Fellowship:

  • Brigham and Women’s Hospital, Hematology & Oncology

Residency:

  • Massachusetts General Hospital, Internal Medicine

Medical School:

  • Albert Einstein College of Medicine

Hospital

Dana Farber Cancer Institute

Specialization

  • CAR T-cell therapy
  • Leukemias
  • Mastocytosis
  • Myelodysplastic syndromes
  • Myeloproliferative disorders

Procedures Performed

  • Leukemia, Acute Lymphoblastic (ALL)
  • Leukemia, Acute Myeloid (AML)
  • Leukemia, Chronic Myelogenous (CML)
  • Leukemias
  • Myelodysplastic Syndromes (MDS)
  • Myeloproliferative Neoplasms (MPNs)

Research & Publications

Treating Leukemias, Myelodysplasia, and Myeloproliferative Disorders

The Adult Leukemia Group is responsible for the diagnosis and treatment of patients with acute and chronic leukemia, myelodysplastic syndrome (MDS), and other stem cell hematopoietic disorders. Our clinical research centers around phase I, II, and III clinical trials in these patients.We recently studied a series of patients with idiopathic hypereosinophilic syndrome (IHES). In collaboration with Drs. Cools and Gilliland, we identified a target gene, the FIP1L1-PDGFRA fusion gene, which is a consequence of an interstitial chromosomal deletion. This finding has led to the explanation of the molecular basis of IHES.Our group is currently working on the development of small molecules to treat acute and chronic leukemias and myelodysplasia. We are testing several small molecules in patients with relapsed or refractory acute myelogenous leukemia, studying the compounds PKC-412, CEP-701, and MLN-518 that specifically inhibit FLT3. Mutations in the FLT3 gene, which encodes a receptor tyrosine kinase, are thought to confer a poor prognosis in patients with acute myelogenous leukemia. We also have clinical trials under way that test histone deacetylase inhibitors in advanced hematologic malignancies. Our approach is to bring novel therapeutic agents to the forefront in the treatment of patients with acute and chronic leukemia, MDS, and myeloproliferative disorders.In addition, our group has been focused on the treatment of acute lymphoblastic leukemia (ALL). We are the lead coordinating site for a large clinical trial using dose-intense pediatric-like regimens for adult patients with ALL. We are also testing novel Notch inhibitor molecules for patients with relapsed or refractory T-cell ALL.

myeloid leukemia. Leukemia. 2012 Sep; 26(9):2061-8.
View in: PubMed

The intersection of genetic and chemical genomic screens identifies GSK-3a as a target in human acute myeloid leukemia. J Clin Invest. 2012 Mar; 122(3):935-47.
View in: PubMed

Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2012 Jan; 10(1):64-110.
View in: PubMed

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33.
View in: PubMed

Chronic myelogenous leukemia. Preface. Hematol Oncol Clin North Am. 2011 Oct; 25(5):ix-x.
View in: PubMed

Chronic myeloid leukemia 2011: successes, challenges, and strategies–proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop. Am J Hematol. 2011 Sep; 86(9):811-9.
View in: PubMed

Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011 Dec; 52(12):2237-53.
View in: PubMed

Candida albicans cervical lymphadenitis in patients who have acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2011 Aug; 11(4):375-7.
View in: PubMed

Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. Am J Hematol. 2011 Jul; 86(7):625-7.
View in: PubMed

Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. Leuk Res. 2011 Dec; 35(12):1611-5.
View in: PubMed

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin. 2011 Jun; 27(6):1263-71.
View in: PubMed

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs. 2012 Jun; 30(3):1121-31.
View in: PubMed

Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer. Expert Opin Ther Targets. 2011 Mar; 15(3):253-64.
View in: PubMed

The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011 Feb; 152(4):452-9.
View in: PubMed

An asymptomatic 61-year-old man with BCR-ABL-positive bone marrow following autologous transplantation for multiple myeloma. Am J Hematol. 2010 Dec; 85(12):944-6.
View in: PubMed

Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations. Am J Hematol. 2010 Dec; 85(12):956-7.
View in: PubMed

Invasive fungal disease in patients treated for newly diagnosed acute leukemia. Am J Hematol. 2010 Sep; 85(9):695-9.
View in: PubMed

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010 Oct 01; 28(28):4339-45.
View in: PubMed

Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A. 2010 Jul 13; 107(28):12617-22.
View in: PubMed

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010 Sep 02; 116(9):1413-21.
View in: PubMed

NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1037-69.
View in: PubMed

When to go FISHing. Am J Clin Pathol. 2010 Mar; 133(3):351-3.
View in: PubMed

Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice. Leuk Lymphoma. 2010 Mar; 51(3):363-75.
View in: PubMed

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1408-14.
View in: PubMed

Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. J Clin Oncol. 2010 Feb 10; 28(5):815-21.
View in: PubMed

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
View in: PubMed

Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009 Oct 06; 16(4):281-94.
View in: PubMed

Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Hematol Oncol Clin North Am. 2009 Oct; 23(5):1121-35, vii-viii.
View in: PubMed

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw. 2009 Oct; 7(9):984-1023.
View in: PubMed

Screens, iron, and leukemia. Blood. 2009 Oct 01; 114(14):2857-8.
View in: PubMed

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 2009 Nov 05; 114(19):4027-33.
View in: PubMed

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol. 2009 Oct; 147(1):97-101.
View in: PubMed

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood. 2009 Aug 27; 114(9):1736-45.
View in: PubMed

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 Jun 10; 301(22):2349-61.
View in: PubMed

Comorbidity description using the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in elderly de novo poor-risk AML patients (pts) treated with laromustine. J Clin Oncol. 2009 May 20; 27(15_suppl):7050.
View in: PubMed

A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML). J Clin Oncol. 2009 May 20; 27(15_suppl):3579.
View in: PubMed

Identification of AML1-ETO modulators by chemical genomics. Blood. 2009 Jun 11; 113(24):6193-205.
View in: PubMed

A forgotten cause of kidney injury in chronic myelomonocytic leukemia. Am J Kidney Dis. 2009 Jul; 54(1):159-64.
View in: PubMed

Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood. 2009 Feb 19; 113(8):1681-8.
View in: PubMed

Disease response to the histone deacetylase inhibitor panobinostat in refractory hodgkin lymphoma. 2008; submitted.

A forgotten cause of renal failure in chronic myelomonocytic leukemia. 2008; submitted.

A dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. 2008; submitted.

Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol. 2008 Oct; 83(10):771-7.
View in: PubMed

Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer. 2008 Oct; 47(10):884-9.
View in: PubMed

A novel SSBP2-JAK2 fusion gene as a result of t(5;9)(q14.3;p24.1) in precursor-B acute lymphocytic leukemia. Cancer Genet Cytogenet. 2008; in press.

Progressive multifocal leukoencephalopathy in a patient with relapsed acute myelogenous leukemia. J Clin Oncol. 2008 Aug 01; 26(22):3804-7.
View in: PubMed

A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2009 Apr; 63(5):859-64.
View in: PubMed

Nelarabine for relapsed t-cell acute lymphoblastic leukemia. Expert Opinion on Pharmacotherapy. 2008; in press.

New agents in acute lymphoblastic leukemia. Current Hematologic Malignancy Reports. 2008; 3(3):in press.

Myelodysplastic Syndromes: Biology and Treatment. Hoffmann R, Benz EJ Jr., Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic Principles and Practice. 2008; in press.

A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M (Cloretazine) in patients (pts) with first relapse of acute myeloid leukemia (AML). American Society of Clinical Oncology (ASCO). 2008; in press.

New agents for the treatment of patients with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2008 Jul; 3(3):135-43.
View in: PubMed

Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass. J Clin Oncol. 2008 Jul 01; 26(19):3279-81.
View in: PubMed

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia. 2008 Sep; 22(9):1707-11.
View in: PubMed

Clinical problem-solving. A joint venture. N Engl J Med. 2008 Jun 05; 358(23):2496-501.
View in: PubMed

Clinical JAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations. Am J Hematol. 2008 Jun; 83(6):519-20.
View in: PubMed

Pharmacokinetic analysis of two dose levels of rasburicase in adult patients with hematologic malignancies at high or potential risk for tumor lysis syndrome. J Clin Oncol. 2008 May 20; 26(15_suppl):14545.
View in: PubMed

A Phase II study of VNP40101M in elderly patients (pts) with de novo poor risk acute myelogenous leukemia (AML). J Clin Oncol. 2008 May 20; 26(15_suppl):7026.
View in: PubMed

A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients (pts) with first relapse of acute myeloid leukemia (AML). J Clin Oncol. 2008 May 20; 26(15_suppl):7051.
View in: PubMed

Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008 Mar 01; 14(5):1446-54.
View in: PubMed

Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia. Semin Oncol. 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20.
View in: PubMed

Hematology-Oncology. Sabatine MS, ed. Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine. 2008; 5-1 to 5-36.

Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med. 2007 Dec 24; 204(13):3059-66.
View in: PubMed

Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies. Blood. 2007; 110(11):276a.

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808. Blood. 2007; 110(11):53a.

JAK2 V617F in Patients with Idiopathic Thromboses in Common Locations. Blood. 2007; 110(11):487a.

II Study of VNP40101M (Cloretazine) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML). Blood. 2007; 110(11):279a.

The KIT Tyrosine Kinase Inhibitor Midostaurine (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis (ASM): Interim Results of a Phase II Trial. Blood. 2007; 110(11):1035A.

Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results. Blood. 2007; 110(11):195B.

A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia. Blood. 2007; 110(11):181a.

A t(4;12)(q11;p13) in a patient with coincident CLL at the same time of AML diagnosis. Atlas Genet Cytogenet Oncol Haematol. 2007.

Role of imatinib-sensitive tyrosine kinases in the pathogenesis of chronic myeloproliferative disorders. Seminars in Oncology. 2007; 44(2 Suppl 2):S17-30.

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007 Jun; 13(6):655-64.
View in: PubMed

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15; 109(12):5136-42.
View in: PubMed

Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol. 2007 Mar 01; 25(7):813-9.
View in: PubMed

Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007 Jan; 13(1):78-83.
View in: PubMed

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1047-55.
View in: PubMed

Systemic mastocytosis: current classification and novel therapeutic options. Clin Adv Hematol Oncol. 2006 Oct; 4(10):768-75.
View in: PubMed

Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007 May; 31(5):599-604.
View in: PubMed

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006 Dec 01; 108(12):3674-81.
View in: PubMed

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006 Nov 15; 108(10):3477-83.
View in: PubMed

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006 Jul; 3(7):e270.
View in: PubMed

A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6585.
View in: PubMed

Dosing of troxacitabine (Troxatyl [T], SGX-145) based on renal function. J Clin Oncol. 2006 Jun 20; 24(18_suppl):2025.
View in: PubMed

Outcome of adolescents with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols, 1991-2000. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9023.
View in: PubMed

A double blind placebo-controlled randomized phase III study of high dose continuous infusion cytosine arabinoside (araC) with or without cloretazine® in patients with first relapse of acute myeloid leukemia (AML). Blood. 2006; 108(11):557a.

Metabolic emergencies in oncology. Chang A, Ganz P, Hayes D, Kinsella T, Pass H, Schiller J, Stone R, Strecher V, eds. Oncology: an evidence-based approach. 2006; 1312-22.

Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed adult patients (pts) with acute myeloid leukemia (AML) under age 61. Blood. 2006; 108(11):50a.

Dosing of troxacitabine (Troxatyl [T], SGX-145) based on renal function. Journal of Clinical Oncology. 2006; 24(18s):85s.

A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. Journal of Clinical Oncology. 2006; 24(18s):357s.

Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML). [Oral presentation]. Blood. 2006; 108(11):51a.

Isochromosome of a deleted 20q may be a relatively common abnormality in myeloid malignancies. Cancer Genet Cytogenet. 2005 Oct 01; 162(1):89-91.
View in: PubMed

The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. Cancer Res. 2005 Aug 15; 65(16):7338-47.
View in: PubMed

Is the cryptic interstitial deletion of 8q24 surrounding MYC a common mechanism in the formation of double minute chromosome? Cancer Genet Cytogenet. 2005 Aug; 161(1):90-2.
View in: PubMed

Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood. 2005 Oct 15; 106(8):2841-8.
View in: PubMed

Leukemia derived dendritic cells (LDCs) may be ineffective as a cancer vaccine for acute myeloid leukemia (AML). J Clin Oncol. 2005 Jun; 23(16_suppl):2527.
View in: PubMed

Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):3131.
View in: PubMed

Vaccine-associated immune and WT-1 responses are associated with better relapse-free survival in patients with AML in remission treated with a GM-CSF secreting leukemia vaccine and autologous stem cell transplant (ASCT). J Clin Oncol. 2005 Jun; 23(16_suppl):6539.
View in: PubMed

Molecularly Targeted Therapies for the Treatment of Acute Myeloid Leukemia. Blumenthal RS, Coombs J, Fennerty B, Goodnight-White S, Kemp J, Kendall D, Lublin F, Mace SE, Wilkens R, eds. Targeted Therapies: Advances in the Treatment of Acute Myeloid Leukemia. 2005; 2(1):17-20.

Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol. 2005 Mar; 33(3):286-94.
View in: PubMed

Managing Chronic Myelogenous Leukemia: An Update. A CE-Certified Activity for Physicians and Nurses. 2005.

Diagnosis of an early precursor-B-ALL presenting with hypereosinophilia using FISH on immunomagnetically selected CD19+ cells [commentary]. Clin Adv Hematol Oncol. 2005; 3(1):64-9.

Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML. Blood. 2005; 106(11):121a.

KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia. 2005 Jan; 19(1):27-30.
View in: PubMed

The treatment of adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2005; 123-30.
View in: PubMed

Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies. Journal of Clinical Oncology. 2005; 23(16s):224s.

The Era of Molecular Therapy: Focus on Chronic Myelogenous Leukemia. 2005.

Vaccine-associated immune and WT-1 responses are associated with better relapse-free survival in patients with AML in remission treated with a GM-CSF secreting leukemia vaccine and autologous stem cell transplant (ASCT). Journal of Clinical Oncology. 2005; 23(16s):569s.

A randomized comparison of induction therapy for untreated acute myeloid leukemia (AML) in patients <60 years using p-glycoprotein (Pgp) modulation with valspodar (PSC833): preliminary results of cancer and leukemia group B study 19808. Blood. 2005; 106(11):122a.

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Onc. 2005; 23:4110-6.

Myelodysplastic Syndromes: Biology and Management. Hoffmann R, Benz EJ Jr., Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic Principles and Practice. 2005; 1195-1208.

Leukemia derived dendritic cells (LDCs) are functionally deficient and inferior to DC leukemia fusion cells as a tumor vaccine for AML. Blood. 2005; 106(11):782a.

 

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

×
Start chat
Need help with cancer treatment?
Scan the code
Hello,
Welcome to CancerFax !

CancerFax is the most trusted international patient facilitator working with top cancer hospital's in the world like MD Anderson, Dana Farber, Asan, NCC Japan, Sheba, Beijing Cancer Institute and Apollo to bring you best of therapies and drugs.

Let us know what services would you like to avail?

1) Cancer treatment in the USA, Japan, Israel, India, Korea or Singapore?
2) CAR T-Cell therapy treatment
3) Cancer vaccine
4) Online video consultation
5) Proton therapy